H.C. Wainwright lowered the firm’s price target on Humacyte (HUMA) to $3 from $4 and keeps a Buy rating on the shares. The firm says the company’s July sales growth suggests potential momentum.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUMA:
- Humacyte Reports Q2 2025 Earnings and Market Expansion
- Buy Rating Reaffirmed for Humacyte Amid Promising Symvess Launch and Strategic Collaborations
- Humacyte reports Q2 EPS (24c), consensus (18c)
- Is HUMA a Buy, Before Earnings?
- Humacyte’s Strategic Positioning and Growth Potential: Buy Rating Affirmed by Josh Jennings